比利時Delphi Genetics S.A.
Delphi Genetics SA 創辦于2001年末,采用其在質粒穩定系統領域的獨家專長開發用于基因工程和細菌中蛋白質表達的更高效的產品和技術。Delphi已獲專利的Staby?技術能夠增加重組蛋白的產量,而不需要像傳統方法那樣使用抗生素。此外,該技術滿足FDA (美國食品和藥物管理局)和EMA (歐洲藥品局)就在人和獸用蛋白質生產工藝中消除耐抗生素基因的各項建議。該公司已經宣布了與賽諾菲-巴斯德公司和葛蘭素史克公司(GSK)等一些重要制藥集團達成的幾項許可協議。
Founded in 2001, Delphi Genetics S.A., located in Gosselies Belgium, focuses on developing new, much more effective products and technologies for gene cloning and protein expression in bacteria.
The products and services developed by Delphi Genetics are based on unique technologies using bacterial poison-antidote genes. Our patented Staby? technology improves DNA cloning reliability and efficiency, allowing successful cloning of genes and expression of recombinant proteins that had been impossible to clone or express with standard methods.
The Staby? technology allows producing proteins and DNA without the use of antibiotics. This is of special importance for large scale protein or DNA productions in the Biopharmaceutical Industry. Our patented stabilization technology dramatically improves the overall production yield and reproducibility. Our technology enables you to implement a completely “antibiotic-free“ production platform thus complying with the latest FDA and EMEA standards.
Through its Staby Operating System, an innovative set of bacterial strains and vectors integrating the Staby technology, Delphi Genetics offers a comprehensive range of molecular tools for DNA cloning and Protein expression.
Through its “Never Clone Alone“ Platform, Delphi Genetics is a dedicated service provider for custom services in Molecular cloning and Gene expression. We also offers research and development services for the biopharmaceutical industry.